Form 4: Alkermes Executive Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Alkermes EVP Craig C. Hopkinson exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Summary
- Craig C. Hopkinson, EVP of R&D and Chief Medical Officer at Alkermes plc, executed a series of transactions involving the company's ordinary shares on January 30, 2025.
- Hopkinson exercised employee stock options to acquire a total of 97,632 ordinary shares at prices ranging from $19.34 to $26.82.
- These options were exercised under a Rule 10b5-1 trading plan adopted on December 14, 2023.
- Concurrently, Hopkinson sold 100,918 ordinary shares at a weighted average price of $32.0496, also under the same 10b5-1 plan.
- The sales were executed in multiple transactions with prices ranging from $32.00 to $32.17.
- Following these transactions, Hopkinson directly owns 44,290 ordinary shares and holds options for 448,329 shares.
Sentiment
Score: 5
Explanation: The document is a routine filing of stock transactions by an executive, which is neither positive nor negative for the company's overall performance.
Industry Context
This is a routine filing for executive stock transactions and is common practice for publicly traded companies. The use of a 10b5-1 plan is a standard method for executives to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the pharmaceutical and biotechnology sectors like Amgen, Biogen, and Gilead Sciences.
- The option exercise and share sale transactions are typical for executive compensation packages, which often include stock options that vest over time.
- The reported prices are within the expected range for Alkermes stock, and the weighted average sale price is consistent with market conditions on the transaction date.
Stakeholder Impact
- The transactions may have a minor impact on the stock price, but are unlikely to significantly affect shareholders due to the pre-planned nature of the trades.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 12/14/2023 | Date the reporting person adopted the Rule 10b5-1 trading plan. |
| 01/30/2025 | Date of the stock option exercises and share sales. |
| 01/31/2025 | Date the Form 4 was signed. |
| 02/20/2030 | Expiration date of some of the stock options. |
| 02/22/2031 | Expiration date of some of the stock options. |
| 02/18/2032 | Expiration date of some of the stock options. |
| 02/23/2033 | Expiration date of some of the stock options. |
Keywords
Alkermes, stock options, insider trading, Form 4, Rule 10b5-1, executive compensation, share sale, equity securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.